HER2 status is commonly assessed in IDC and is considered an independent prognostic factor for poor outcomes.295 However, the predictive value of HER2 for DCIS progression and recurrence remains controversial. This evidence concerns the gene ERBB2 and ductal breast carcinoma in situ.